- Home
- ABEO vs NYXH Comparison
ABEO vs NYXH Comparison
Compare ABEO & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- NYXH
- Stock Information
- Founded
- ABEO 1974
- NYXH 2009
- Country
- ABEO United States
- NYXH Belgium
- Employees
- ABEO N/A
- NYXH N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- NYXH Medical/Dental Instruments
- Sector
- ABEO Health Care
- NYXH Health Care
- Exchange
- ABEO Nasdaq
- NYXH Nasdaq
- Market Cap
- ABEO 256.9M
- NYXH 222.3M
- IPO Year
- ABEO 1980
- NYXH 2021
- Fundamental
- Price
- ABEO $5.57
- NYXH $7.55
- Analyst Decision
- ABEO Strong Buy
- NYXH Strong Buy
- Analyst Count
- ABEO 6
- NYXH 4
- Target Price
- ABEO $18.00
- NYXH $14.50
- AVG Volume (30 Days)
- ABEO 1.1M
- NYXH 43.9K
- Earning Date
- ABEO 08-11-2025
- NYXH 08-05-2025
- Dividend Yield
- ABEO N/A
- NYXH N/A
- EPS Growth
- ABEO N/A
- NYXH N/A
- EPS
- ABEO N/A
- NYXH N/A
- Revenue
- ABEO N/A
- NYXH $4,716,818.00
- Revenue This Year
- ABEO N/A
- NYXH $323.07
- Revenue Next Year
- ABEO $323.51
- NYXH $204.30
- P/E Ratio
- ABEO N/A
- NYXH N/A
- Revenue Growth
- ABEO N/A
- NYXH N/A
- 52 Week Low
- ABEO $3.93
- NYXH $5.55
- 52 Week High
- ABEO $7.32
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- ABEO 37.51
- NYXH 49.76
- Support Level
- ABEO $5.66
- NYXH $7.30
- Resistance Level
- ABEO $6.24
- NYXH $7.67
- Average True Range (ATR)
- ABEO 0.26
- NYXH 0.24
- MACD
- ABEO -0.08
- NYXH -0.06
- Stochastic Oscillator
- ABEO 8.08
- NYXH 32.99
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.